We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: JNJ, Eli Lilly, Merck, AbbVie and GSK
Read MoreHide Full Article
For Immediate Release
Chicago, IL – October 15, 2020 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Johnson & Johnson (JNJ - Free Report) , Eli Lilly (LLY - Free Report) , Merck (MRK - Free Report) , AbbVie (ABBV - Free Report) and Glaxo (GSK - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Do J&J Q3 Earnings Results Indicate a Sales Recovery for Big Pharma?
Johnson & Johnson is usually the first pharma company to report quarterly earnings. It reported encouraging third-quarter results, beating third-quarter estimates for earnings and sales. The drug and medical device giant also raised its full-year earnings and sales guidance for the second time this year.
How Did J&J’s Segments Perform
Its Pharmaceuticals unit continued to outperform the market as the company witnessed improved trends in prescription volumes and physician office visits. The sales increase was led by higher penetration and new indications across key products, such as Darzalex, Imbruvica and Stelara, which offset the impact of biosimilar and generic competition on some drugs, and the continued delays in diagnosis and slower new patient starts for some other drugs due to COVID-19.
Meanwhile, increasing demand for its Consumer Health products and a better-than-expected procedure recovery in Medical Devices provided top-line support. Thepandemic hit J&J’s Medical Devices segment the hardest due to a widespread decline in elective surgical procedures and the redeployment of hospital resources to address patients affected by COVID-19. However, the segment was much less affected in the third quarter due to better-than-expected market recovery as medical procedures are ramping up faster than expected.
In fact, faster-than-expected recovery in sales of the Medical Devices unit was the primary factor, which coaxed the company to raise its financial outlook for the year.
What Do J&J’s Results Mean for Others?
J&J is the first of the big drugmakers to report earnings for the third quarter. Investors typically look at this company’s results for signals regarding how the rest of the big drugmakers will fare.
Most large drugmakers expect their sales trends to have improved in the third quarter after a brutal second quarter. In the second quarter, demand trends of drugs, those administered in a physician’s office, were hurt by COVID-19-related business disruptions, while reversal of stockpiling benefits in the first quarter also hurt most companies’ top line. However, drugmakers expect improved business conditions with global economies re-opening to have resulted in increased sales in the quarter to be reported.
This was reflected in J&J’s Q3 results. All its segments performed well despite the negative impact of COVID-19 and the company expects to see continued improvement through the end of the year. Going forward, J&J expects continued procedure stabilization in the Medical Devices unit, solid volume-driven above-market growth in the Pharmaceuticals unit and competitive growth in the Consumer Health segment.
J&J’s strong third-quarter results and a bullish outlook for the rest of the year make us optimistic that most large drugmakers like Eli Lilly, Merck, AbbVie, AstraZeneca, Glaxo and others, should report better-than-expected results for the third quarter.
The upcoming election could be a massive buying opportunity for savvy investors. Trillions of dollars will shift into new market sectors after the election. The question is, which sectors will soar for each candidate? Zacks has put together a new special report to help readers like you target big profits.
The 2020 Election Stock Report reveals specific stocks you’ll want to own immediately after the results are announced – 6 if Trump wins, 6 if Biden wins. Past election reports have led investors to gains of +71%, +83%, even +185% in the following months. This year’s picks could be even more lucrative.
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: JNJ, Eli Lilly, Merck, AbbVie and GSK
For Immediate Release
Chicago, IL – October 15, 2020 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Johnson & Johnson (JNJ - Free Report) , Eli Lilly (LLY - Free Report) , Merck (MRK - Free Report) , AbbVie (ABBV - Free Report) and Glaxo (GSK - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Do J&J Q3 Earnings Results Indicate a Sales Recovery for Big Pharma?
Johnson & Johnson is usually the first pharma company to report quarterly earnings. It reported encouraging third-quarter results, beating third-quarter estimates for earnings and sales. The drug and medical device giant also raised its full-year earnings and sales guidance for the second time this year.
How Did J&J’s Segments Perform
Its Pharmaceuticals unit continued to outperform the market as the company witnessed improved trends in prescription volumes and physician office visits. The sales increase was led by higher penetration and new indications across key products, such as Darzalex, Imbruvica and Stelara, which offset the impact of biosimilar and generic competition on some drugs, and the continued delays in diagnosis and slower new patient starts for some other drugs due to COVID-19.
Meanwhile, increasing demand for its Consumer Health products and a better-than-expected procedure recovery in Medical Devices provided top-line support. Thepandemic hit J&J’s Medical Devices segment the hardest due to a widespread decline in elective surgical procedures and the redeployment of hospital resources to address patients affected by COVID-19. However, the segment was much less affected in the third quarter due to better-than-expected market recovery as medical procedures are ramping up faster than expected.
In fact, faster-than-expected recovery in sales of the Medical Devices unit was the primary factor, which coaxed the company to raise its financial outlook for the year.
What Do J&J’s Results Mean for Others?
J&J is the first of the big drugmakers to report earnings for the third quarter. Investors typically look at this company’s results for signals regarding how the rest of the big drugmakers will fare.
Most large drugmakers expect their sales trends to have improved in the third quarter after a brutal second quarter. In the second quarter, demand trends of drugs, those administered in a physician’s office, were hurt by COVID-19-related business disruptions, while reversal of stockpiling benefits in the first quarter also hurt most companies’ top line. However, drugmakers expect improved business conditions with global economies re-opening to have resulted in increased sales in the quarter to be reported.
This was reflected in J&J’s Q3 results. All its segments performed well despite the negative impact of COVID-19 and the company expects to see continued improvement through the end of the year. Going forward, J&J expects continued procedure stabilization in the Medical Devices unit, solid volume-driven above-market growth in the Pharmaceuticals unit and competitive growth in the Consumer Health segment.
J&J’s strong third-quarter results and a bullish outlook for the rest of the year make us optimistic that most large drugmakers like Eli Lilly, Merck, AbbVie, AstraZeneca, Glaxo and others, should report better-than-expected results for the third quarter.
J&J currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Have You Seen Zacks’ 2020 Election Stock Report?
The upcoming election could be a massive buying opportunity for savvy investors. Trillions of dollars will shift into new market sectors after the election. The question is, which sectors will soar for each candidate? Zacks has put together a new special report to help readers like you target big profits.
The 2020 Election Stock Report reveals specific stocks you’ll want to own immediately after the results are announced – 6 if Trump wins, 6 if Biden wins. Past election reports have led investors to gains of +71%, +83%, even +185% in the following months. This year’s picks could be even more lucrative.
Check out Zacks’ 2020 Election Stock Report >>
Join us on Facbook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.